Back

Chronic outcomes of leadless vs transvenous single chamber ventricular pacemakers in high-risk subgroups

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Pacing innovations Antibradycardia Pacing ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Mr Lucas Higuera

Medtronic, Mounds View (United States of America)

5 More presentations in this session

Presentation thumbnail
Clinical impact of "minimal" right ventricular pacing on atrial arrhythmias: results from the prospective multi-center worldwide EMERALD study.
Doctor A. Di Cori (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
Mortality and 30-day readmission rate following leadless pacemaker implantation: insights from the Nationwide Readmissions Database
Doctor R. Tonegawa-Kuji (Suita, JP)
Abstract Slides Video
Presentation thumbnail
Evaluation of the association between right ventricular lead placement and future need for upgrade from pacemaker or ICD to cardiac resynchronization therapy. A population-based comparative study
Associate Professor R. Borgquist (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Acute hemodynamic effects of biventricular pacing studied during cardiovascular magnetic resonance imaging: The PICARIA Trial
Mr L. Hopman (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
Intracardiac echocardiographically guided permanent pacemaker implantation is a feasible imaging tool with comparable procedural efficacy and safety
Professor S. Shin (Ansan, KR)
Abstract Slides Video

Access the full session

Session thumbnail
Pacing innovations

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Why choose leadless over transvenous pacemakers?
thumbnail
Congress Presentation
Impact of comorbidities on survival and complications in patients implanted with leadless pacemakers: a national, multicenter study
thumbnail
Congress Presentation
Which patients can benefit from advances in leadless pacemaker therapy beyond current guidelines?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources